You are here
- Home
- Therapy Areas
- Oncology/Infection
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
- Disease
- breast cancer
- Drug Name
- Faslodex
- Generic Name
- fulvestrant
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- II
- Start Date
- Mar 15, 2000
- Study Name
- D6995L00005
- Study Id
- 9238SZ/0001
- ClinicalTrials.gov ID
- NCT00272740
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
